Valuation: Nexstim Plc

Market Cap 77.03M 87.48M 72.99M 65.89M 124M 8.39B 126M 873M 336M 4.29B 328M 321M 13.75B P/E 2026 *
95.4x
P/E 2027 * 41.5x
Enterprise Value 75.38M 85.61M 71.42M 64.48M 122M 8.21B 123M 855M 329M 4.2B 321M 314M 13.45B EV / Sales 2026 *
5.67x
EV / Sales 2027 * 4.77x
Free-Float
59.35%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 2020-02-10
Director of Finance/CFO 40 2020-02-10
Chief Tech/Sci/R&D Officer 65 2007-12-31
Director TitleAgeSince
Director/Board Member 64 2019-11-10
Chairman 63 2019-11-10
Director/Board Member 55 2021-04-30
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-0.86% - - 87.48M
-0.67%+1.47%+39.18%+33.36% 250B
-2.02%-0.00%+11.75%-10.70% 156B
-1.35%+2.09%-9.08%+39.12% 144B
-0.52%-2.17%-55.29%-17.33% 63.26B
-2.00%-0.58%+10.99%+24.60% 49.75B
-1.55%+4.23%+34.25%+54.10% 48.58B
-0.93%+0.89%-18.92%-21.91% 47.99B
+2.47%+5.43%-4.18%+40.30% 46.22B
-0.87%+4.47%+46.56%+60.24% 43.17B
Average -0.85%+2.27%+6.14%+22.42% 94.22B
Weighted average by Cap. -1.00%+2.37%+11.71%+21.76%

Financials

2026 *2027 *
Net sales 13.3M 15.1M 12.6M 11.38M 21.44M 1.45B 21.72M 151M 58.02M 740M 56.71M 55.48M 2.37B 15.55M 17.66M 14.73M 13.3M 25.07M 1.69B 25.39M 176M 67.83M 866M 66.31M 64.86M 2.78B
Net income 750K 852K 711K 642K 1.21M 81.66M 1.22M 8.5M 3.27M 41.75M 3.2M 3.13M 134M 1.85M 2.1M 1.75M 1.58M 2.98M 201M 3.02M 20.97M 8.07M 103M 7.89M 7.72M 330M
Net Debt -1.65M -1.87M -1.56M -1.41M -2.66M -180M -2.69M -18.7M -7.2M -91.84M -7.04M -6.88M -294M -2.8M -3.18M -2.65M -2.4M -4.51M -305M -4.57M -31.74M -12.21M -156M -11.94M -11.68M -500M
Logo Nexstim Plc
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-